---
title: Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young
  Patients with Newly Diagnosed AML
date: '2025-02-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/40009498/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250227170931&v=2.18.0.post9+e462414
source: Blood
description: Venetoclax combined with hypomethylating agents is approved for frontline
  therapy in older/unfit acute myeloid leukemia (AML) patients. However, prospective
  data on this low intensity therapy in treatment-naive younger AML patients are lacking.
  This study investigated the efficacy and safety of venetoclax plus decitabine (VEN-DEC)
  as induction in untreated young fit AML patients in a randomized trial. Patients
  aged 18-59 years eligible for intensive chemotherapy were randomized 1:1 to ...
disable_comments: true
---
Venetoclax combined with hypomethylating agents is approved for frontline therapy in older/unfit acute myeloid leukemia (AML) patients. However, prospective data on this low intensity therapy in treatment-naive younger AML patients are lacking. This study investigated the efficacy and safety of venetoclax plus decitabine (VEN-DEC) as induction in untreated young fit AML patients in a randomized trial. Patients aged 18-59 years eligible for intensive chemotherapy were randomized 1:1 to ...